Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation

By sjmartinez • February 9, 2024

abatacept, acitretin, adalimumab, apremilast, biologics, brodalumab, certolizumab, cyclosporine, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, vaccination, vaccines,

Tags: abatacept, acitretin, adalimumab, apremilast, Biologics, brodalumab, certolizumab, cyclosporine, Dermatology, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, Publications, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, Vaccination, vaccines

Workplace Accommodations for Alopecia Areata: A Framework for Dermatologists

Taghizadeh CS, Goh C, Lipner SR. Workplace Accommodations for Alopecia Areata: A Framework for Dermatologists. Clin Dermatol. 2026 Sep 22:S0738-081X(26)00269-5. doi: 10.1016/j.clindermatol.2026.09.022. Epub ahead of[...]

Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study

Curman P, Thapa M, Ludwig RJ, Kasperkiewicz M. Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study. J Eur Acad[...]

Temporal CRAC channel blockade modulates the MYC-MXD axis to attenuate autoimmune inflammation

Wu B, Hasiakos S, Cokus S, Do M, Kaplan E, Pellegrini M, Sun Z, Kim RH, Srikanth S, Gwack Y. Temporal CRAC channel blockade modulates[...]